HLA-C and leukemia: To determine whether the anti-leukemia activity of NY-ESO-1-specific TCR-T cells was MHC dependent, we incubated DAC-treated U937-A2+, HL60-A2+, and Kasumi-1-A2+ cells with an MHC class I mAb (W6/32 mAb) or isotype control (IgG2a).